BACKGROUND: The recent decline in US breast cancer incidence rates has been attributed to the marked reduction in use of postmenopausal hormone therapy (HT). An alternative explanation is that women who are not routinely seeking medical care to renew HT prescriptions may be less adherent to recommendations for mammographic screening. To investigate the latter possibility, we compared mammographic intervals according to HT use. METHODS: Using data (1995-2007) from the New Hampshire Mammography Network (NHMN), a state-based mammography registry, we assessed mammographic intervals corresponding to HT use or nonuse among postmenopausal women. We used linear mixed effects models to assess whether the length of screening mammogram intervals differed according to HT use. RESULTS: A total of 310,185 mammograms, representing 76,192 postmenopausal women and 319,353 person-years of screening, were included in the analysis. The median screening interval corresponding to HT use overall was 13.0 months (interquartile range: 12.4-15.1) and for nonuse was 13.1 (interquartile range: 12.4-15.8). Virtually, all screening mammograms occurred within a 2-year interval regardless of HT use or nonuse (98.5 and 98.1%, respectively). CONCLUSIONS: Our findings indicate that screening mammography intervals are similar whether or not women are using HT. Thus, reduced utilization of screening mammography is unlikely to account for the decrease in breast cancer incidence seen soon after the WHI report.
BACKGROUND: The recent decline in US breast cancer incidence rates has been attributed to the marked reduction in use of postmenopausal hormone therapy (HT). An alternative explanation is that women who are not routinely seeking medical care to renew HT prescriptions may be less adherent to recommendations for mammographic screening. To investigate the latter possibility, we compared mammographic intervals according to HT use. METHODS: Using data (1995-2007) from the New Hampshire Mammography Network (NHMN), a state-based mammography registry, we assessed mammographic intervals corresponding to HT use or nonuse among postmenopausal women. We used linear mixed effects models to assess whether the length of screening mammogram intervals differed according to HT use. RESULTS: A total of 310,185 mammograms, representing 76,192 postmenopausal women and 319,353 person-years of screening, were included in the analysis. The median screening interval corresponding to HT use overall was 13.0 months (interquartile range: 12.4-15.1) and for nonuse was 13.1 (interquartile range: 12.4-15.8). Virtually, all screening mammograms occurred within a 2-year interval regardless of HT use or nonuse (98.5 and 98.1%, respectively). CONCLUSIONS: Our findings indicate that screening mammography intervals are similar whether or not women are using HT. Thus, reduced utilization of screening mammography is unlikely to account for the decrease in breast cancer incidence seen soon after the WHI report.
Authors: M M Roberts; F E Alexander; T J Anderson; U Chetty; P T Donnan; P Forrest; W Hepburn; A Huggins; A E Kirkpatrick; J Lamb Journal: Lancet Date: 1990-02-03 Impact factor: 79.321
Authors: G A Colditz; M J Stampfer; W C Willett; D J Hunter; J E Manson; C H Hennekens; B A Rosner; F E Speizer Journal: Cancer Causes Control Date: 1992-09 Impact factor: 2.506
Authors: Rowan T Chlebowski; Lewis H Kuller; Ross L Prentice; Marcia L Stefanick; JoAnn E Manson; Margery Gass; Aaron K Aragaki; Judith K Ockene; Dorothy S Lane; Gloria E Sarto; Aleksandar Rajkovic; Robert Schenken; Susan L Hendrix; Peter M Ravdin; Thomas E Rohan; Shagufta Yasmeen; Garnet Anderson Journal: N Engl J Med Date: 2009-02-05 Impact factor: 91.245
Authors: Diana S M Buist; Rod Walker; Erin J Aiello Bowles; Patricia A Carney; Stephen H Taplin; Tracy Onega; Karla Kerlikowske; Walter Clinton; Diana L Miglioretti Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-02-01 Impact factor: 4.254
Authors: Kerryn W Reding; David R Doody; Anne McTiernan; Li Hsu; Scott Davis; Janet R Daling; Peggy L Porter; Kathleen E Malone Journal: Breast Cancer Res Treat Date: 2010-09-29 Impact factor: 4.872